Application of exosome miRNA in preparation of medicines or whitening cosmetics

By inducing the expression of exosome miR-574-5p in mouse B16 melanoma cells, the transport of melanosome to human keratinocytes is significantly inhibited, and exosome miRNA in the treatment of skin pigmentation diseases in the prior art has been solved. Inadequately, it provides safe and effective whitening skin care raw materials.

CN118903179APending Publication Date: 2024-11-08JIMEI UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411056877.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

In the prior art, there are few studies on exosomal miRNAs reducing epidermal melanin levels by inhibiting melanin transport, especially the exosomal miRNA function mediated by marine microalgae active substances has not been reported, and it is difficult to correlate skin pigmentation. Disease drugs and whitening skin care products are developed to provide safe raw materials.

Method used

Mice B16 melanoma cells were treated with ceramide Ehux-C22 to induce the expression of exosome secreted miR-574-5p and extracted by ultracentrifugation, which significantly inhibited the transport of melanosomes to human keratinocytes and was a whitening skin care product Provide novel exosomal miRNA raw materials.

Benefits of technology

miR-574-5p can significantly inhibit the transport of melanosome without affecting the normal melanin synthesis-related metabolism of cells, providing a safe and effective whitening skin care raw material, solving the treatment problems of skin pigmentation-related diseases. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004976697770000071
    Figure BDA0004976697770000071
  • Figure HDA0004976697780000011
    Figure HDA0004976697780000011
  • Figure HDA0004976697780000021
    Figure HDA0004976697780000021
Patent Text Reader

Abstract

The invention provides an application of exosome miRNA in preparation of drugs or whitening cosmetics, and particularly relates to an application of exosome miR-574-5p in preparation of drugs for inhibiting melanosome transport, after mouse B16 melanoma cells are treated by ceramide Ehux-C22, expression of secreted exosome miR-574-5p is induced, then B16 cell exosome is extracted by adopting an ultracentrifugation method, and the drug for inhibiting melanosome transport is obtained. And the exosome miR-574-5p is obtained after the reaction is completed. The miR-574-5p can be used for remarkably inhibiting the transfer of melanosome to human keratinocytes, and a novel and feasible exosome miRNA raw material is provided for a whitening skin care product.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of exosomes, and specifically to the application of exosome miRNA in the preparation of medicines or whitening cosmetics. Background Art

[0002] Skin pigmentation is the result of the interaction between melanocytes and keratinocytes. Melanin is transported from melanocytes to keratinocytes to protect the skin from harmful ultraviolet radiation and prevent the development of cancer. However, abnormal accumulation of pigment can lead to a series of skin diseases such as melasma, spots, skin cancer and post-inflammatory pigmentation. By reducing melanin levels or inhibiting melanosome transport, pigmentation can be effectively reduced and skin problems caused by excessive pigment accumulation can be improved. At present, research on the regulation of skin melanin levels mainly focuses on melanin synthesis and degradation in melanocytes.

[0003] MicroRNA can regulate gene expression by specifically binding to the 3'-UTR of the target gene mRNA. At present, it has been determined that multiple miRNAs can directly or indirectly act on genes related to melanin synthesis, transport and metabolism, thereby affecting pigmentation. Exosomes are a type of nano-scale vesicles actively secreted by cells, with a diameter of about 50 to 150 nm and a lipid bilayer membrane structure. They can be released from different cell types and contain functional mRNA, miRNA, proteins, lipids and other molecules. They are considered to be information transfer media between cells, and their role in surrounding cells or distal tissues is more important. At present, there are few reports on the research on exosomal miRNA reducing epidermal melanin levels by inhibiting melanin transport, especially the research on the related functions of exosomal miRNA mediated by active substances from marine microalgae. If exosomal miRNA can achieve the anti-melanin effect without affecting the normal melanin synthesis-related metabolism of cells, this will provide a safer source of raw materials for the development of drugs for skin pigmentation-related diseases and whitening skin care products. Summary of the invention

[0004] The present invention aims to solve the key technical problems in the research and development of the above products to a certain extent.

[0005] To this end, in the first aspect of the present invention, the present invention proposes the use of exosomal miR-574-5p in the preparation of a drug for inhibiting melanosome transport, wherein mouse B16 melanoma cells are treated with ceramide Ehux-C22 to induce the expression of secreted exosomal miR-574-5p, and then the B16 cell exosomes are extracted by ultracentrifugation to obtain the exosomal miR-574-5p.

[0006] According to the application of the present invention, after treating mouse B16 melanoma cells with ceramide Ehux-C22, the expression of secreted exosome miR-574-5p is induced. MiR-574-5p can significantly inhibit the transport of melanosomes to human keratinocytes, providing a novel and feasible exosome miRNA raw material for whitening skin care products.

[0007] Optionally, the ceramide Ehux-C22 is extracted from the marine coccolithophore Emiliania huxley BOF92.

[0008] Optionally, the exosomal miR-574-5p inhibits the transport of melanosomes to human keratinocytes.

[0009] Optionally, the final concentration of the ceramide Ehux-C22 is 2 μM.

[0010] In the second aspect of the present invention, there is provided an application of exosomal miR-574-5p in the preparation of skin whitening cosmetics, wherein mouse B16 melanoma cells are treated with ceramide Ehux-C22 to induce the expression of secreted exosomal miR-574-5p, and then the B16 cell exosomes are extracted by ultracentrifugation to obtain the exosomal miR-574-5p.

[0011] According to the application of the present invention, after treating mouse B16 melanoma cells with ceramide Ehux-C22, the expression of secreted exosome miR-574-5p is induced. MiR-574-5p can significantly inhibit the transport of melanosomes to human keratinocytes, providing a novel and feasible exosome miRNA raw material for whitening skin care products.

[0012] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1 A cluster diagram of differentially expressed miRNAs in B16 cell exosomes according to an embodiment of the present invention;

[0014] Figure 2 The qRT-PCR detection result of B16 cell exosome miR-574-5p according to the embodiment of the present invention;

[0015] Figure 3 is a diagram of a melanosome structure under a projection electron microscope according to an embodiment of the present invention;

[0016] Figure 4 The effect of overexpression of miR-574-5p on the activity of keratinocyte Hacat according to an embodiment of the present invention;

[0017] Figure 5 Graph showing the effect of overexpression of miR-574-5p on melanin levels in keratinocytes Hacat according to an embodiment of the present invention. DETAILED DESCRIPTION

[0018] Embodiments of the present invention are described in detail below, examples of which are shown in the accompanying drawings, wherein the same or similar reference numerals throughout represent the same or similar elements or elements having the same or similar functions. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, and should not be construed as limiting the present invention.

[0019] The disclosure below provides many different embodiments or examples to realize different implementation methods of the present invention. In order to simplify the disclosure of the present invention, specific embodiments or examples are described below. Of course, they are only examples, and the purpose is not to limit the present invention. In addition, the examples of various specific processes and materials provided by the present invention, and those of ordinary skill in the art can be aware of the applicability of other processes and / or the use of other materials. Unless otherwise stated, the implementation of the present invention will adopt the traditional techniques in the fields of chemistry, molecular biology, etc. within the capabilities of those skilled in the art. In addition, unless otherwise stated, in this article, nucleic acids are written from left to right in the direction of 5' to 3', and amino acid sequences are written from left to right in the direction of amino terminal to carboxyl terminal.

[0020] It should be noted that in the following examples, materials: ceramide Ehux-C22 was extracted from marine coccolithophore Emiliania huxley BOF92 (the extraction method refers to the patent "A method for extracting ceramide from marine coccolithophore", patent authorization number: ZL 201810043725.7); mouse B16 melanoma cells (Shanghai, China); human immortalized epidermal cells Hacat were purchased from Beina Lianchuang Biotechnology Research Institute (Henan, China).

[0021] Reagents: fetal bovine serum (FBS, Gemini, Australia); exosome-depleted fetal bovine serum (Shanghai Xiaopeng Biotechnology Co., Ltd.); DMEM serum-free medium (Gibco, USA); RPMI-1640 serum-free medium (Gibco, USA); Opti-MEM serum-free medium (Gibco, USA); streptomycin / penicillin mixture (BI, Israel); 0.25% Trypsin-EDTA trypsin (Gibco, USA); Phosphate buffered saline buffer (PBS, Hyclone, USA); dimethyl sulfoxide (DMSO, Amresco, USA); methyl tert-butyl ether (MTBE, Sigma, USA); TRIzol regent kit (Invitrogen, USA); isopropanol (Sinopharm Chemical Reagent Co., Ltd.); chloroform (Sinopharm Chemical Reagent Co., Ltd.); anhydrous ethanol (Sinopharm Chemical Reagent Co., Ltd.); DEPC-treated water (Beijing Rambolide Biotechnology Co., Ltd.).

[0022] Instruments: Inverted microscope (Motic Co., Ltd.); Multifunctional ELISA analyzer (Biotek, USA); CO 2 Incubator (Thermo Corporation, USA); analytical balance (Ohaus Instrument Co., Ltd.); high-speed refrigerated centrifuge (Eppendorf, Germany); constant temperature metal bath (Tiangen Biochemical Technology Co., Ltd.); ultra-micro-spectrophotometer (Implen GmbH, Germany); Real-Time PCR System (Roche, USA); projection electron microscope (Talos L120CTEM, USA).

[0023] The present invention is described below by means of illustrative specific examples, which are not intended to limit the scope of the present invention in any way. It is particularly noted that the reagents used in the present invention are commercially available unless otherwise specified.

[0024] Example 1 Treatment of B16 cells with ceramide Ehux-C22

[0025] (1) B16 cells were taken out of liquid nitrogen and revived in a water bath at 37°C. B16 cells were inoculated in 1640 complete medium (10% fetal bovine serum and 1% double antibody) and cultured in a cell culture incubator (37°C, 5% CO2).

[0026] (2) When the confluence of B16 cells reached 80%, the cells were digested with trypsin (containing 0.05% EDTA) for 2 min, and the same volume of 1640 complete medium was immediately added to terminate the digestion.

[0027] (3) Take a small amount of B16 cell suspension and count it. Inoculate approximately 180×10 cells in each 15 cm culture dish. 4 cells, supplement 1640 complete medium to 25 mL, divide the inoculated culture dishes into two groups: experimental group (Exp) and control group (Con), set up 3 biological replicates in each group, and continue to culture in the cell culture incubator for 12 h.

[0028] (4) When B16 cells were completely attached and balanced, the culture medium in the culture dish was aspirated, and 5 mL of PBS was added for washing, and the process was repeated three times. 25 mL of DMEM culture medium (10% exosome-free fetal bovine serum + 1% double antibody) was added to each culture dish of the Con group and the Exp group. The ceramide Ehux-C22 with a final concentration of 2 μM was additionally added to the Exp group, and the cells were cultured in the incubator for another 48 h.

[0029] (5) The B16 cell supernatant was collected to extract exosomes, and the B16 cell pellet was collected and stored in a -80°C ultra-low temperature refrigerator. The cell pellet was used for subsequent total RNA extraction.

[0030] Example 2 Isolation of exosomes from B16 cells

[0031] Exosomes from B16 cells were extracted by ultracentrifugation.

[0032] (1) After culturing for 48 h in step (4) of Example 1, centrifuge at 300 g and 4° C. for 10 min and collect the supernatant (at least four 150-cm 2 Petri dish);

[0033] (2) Centrifugation at 2000 g and 4°C for 10 min (to remove dead cells in the culture medium);

[0034] (3) Centrifugation at 10,000 g and 4°C for 30 min, repeated twice (to remove cell debris);

[0035] (4) Replace the supernatant into an ultracentrifuge tube, balance with PBS (at least to two decimal places), centrifuge at 100,000 g and 4°C for 70 min, and discard the supernatant;

[0036] (5) The pellet was resuspended in 200 μL PBS to obtain an exosome suspension. Part of the suspension was stored in a 4 °C refrigerator for exosome characterization (up to 1 week), and part of the suspension was stored in a -80 °C ultra-low temperature refrigerator.

[0037] Example 3 qRT-PCR detection of miR-574-5p expression level

[0038] (1) Combined with B16 cell exosome miRNA omics analysis, differentially expressed miRNAs were screened ( Figure 1 );

[0039] (2) Fluorescence quantitative detection of differentially expressed miR-574-5p. Primer Premier 5 software was used to design the primers for miR-574-5p. The primer sequence was TGAGTGTGTGTGTGTGTGAGTGTGT (SEQ ID NO: 1). U6 was selected as the internal reference. The primer sequence was F: CTCGCTTCGGCAGCACA, (SEQ ID NO: 2) R: AACGCTCACGAATTTGCGT (SEQ ID NO: 3). It was synthesized by Shanghai Bioengineering.

[0040] (3) Reverse transcription of miRNA in cells and exosomes to synthesize cDNA. The reaction system is: 2xmiRNA RTReaction Buffer, 10μL; miRNA RT Enzyme Mix, 2μL; Total RNA, 2μg; RNase-Free ddH2O, supplemented to 20μL. The reaction conditions are: 42℃, 60min; 95℃, 4min. cDNA is stored in an ultra-low temperature refrigerator at -80℃;

[0041] (4) qRT-PCR was performed using the Tiangen miRcute enhanced miRNA fluorescence quantitative kit. The reaction system was: Forward Primer (10 μM), 0.4 μL; Reserve Primer (10 μM), 0.4 μL; 2xmiRcute Plus miRNAPreMix, 10 μL; Template cDNA, 100 ng; ddH2O was added to 20 μL;

[0042] (5) The qRT-PCR reaction program was set on the fluorescence quantitative instrument as follows: pre-deformation (95°C, 40 s); cycle reaction (95°C, 10 s, 60°C, 45 s), 40 cycles; melting curve (95°C, 15 s, 60°C, 30 s, 95°C, 10 s, 60°C, 15 s), using 2 -ΔΔCt The relative expression of miRNA was calculated by Figure 2 shown.

[0043] Example 4 Extraction of B16 cell melanosomes

[0044] (1) Use 150-mm 2 B16 cells were cultured in culture dishes (at least 30 dishes). When the confluence reached more than 90%, the culture medium was discarded, 5 mL of trypsin was added to each dish for digestion for 2 min, and the cell pellet was collected by centrifugation at 500 g for 5 min;

[0045] (2) Wash the cell pellet once with 10 mL of cell homogenization buffer, centrifuge at 1000 g, 4°C for 10 min, and remove the supernatant;

[0046] (3) Resuspend the cells in 10 mL of CHM solution and grind the cells about 40 times using a glass homogenizer on ice. Transfer the homogenate to a 15 mL centrifuge tube and use an 18 G needle to draw the solution into a syringe. Then replace the needle with a 27 G needle and put the solution back into the iced 15 mL centrifuge tube. Repeat the injection 5 times.

[0047] (4) Centrifuge at 600 g for 10 min at 4°C, discard the precipitate, and collect the supernatant (approximately 8 mL);

[0048] (5) Using a pipette, spread a 1.0 to 2.0 M sucrose gradient in a 36.5 mL ultracentrifuge tube (sucrose concentrations, from top to bottom: 1.0, 1.2, 1.4, 1.5, 1.6, 1.8, and 2.0 M; 4 mL each), gently spread the supernatant obtained in (3) on top of the sucrose gradient (mark the outside of the tube with a marker to facilitate subsequent identification of gradient fractions), and centrifuge at 4°C, 100,000 g for 1 h;

[0049] (6) Carefully collect each layer of gradient solution from the top of the ultracentrifuge tube using a 12 mL syringe and transfer each layer of recovered solution into a new 36.5 mL ultracentrifuge tube;

[0050] (7) Add 30 mL of melanosome washing buffer (MWB) solution to a new ultracentrifuge tube, mix well, centrifuge at 12,000 g for 30 min at 4°C, and remove the supernatant;

[0051] (8) Resuspend the pellet in 5 mL of PBS and wash once. Centrifuge at 5000 g for 20 min at 4°C. Remove the supernatant and resuspend the pellet in 1 mL of PBS.

[0052] Purified melanosomes such as Figure 3 As shown, Figure 3 In the figure, A: stage I melanosomes; B: stage II melanosomes; C: stage III melanosomes; D: stage IV melanosomes. The scale bar is 0.5 μm. The arrows in the figure refer to M-Ⅰ, M-II, M-III, M-IV: stage I, II, III, and IV melanosomes. The internal structure of stage I melanosomes is incomplete, lacking melanin, and mostly spherical vesicles ( Figure 3 A); Phase II melanosomes become oval as the vesicles are elongated, showing a good organizational structure, with luminal fibril stripes inside ( Figure 3 B); In stage III melanosomes, melanin deposition on the fibril stripes becomes obvious, and the melanosomes become thicker and darker ( Figure 3 C); Stage IV melanosomes are completely filled with melanin, forming mature melanosomes ( Figure 3 D).

[0053] Example 5 Keratinocytes overexpress miR-574-5p

[0054] Culture keratinocytes in DMEM complete medium until the confluence is 70%-80%, taking a six-well plate as an example:

[0055] (1) miR-NC (negative control vector without miR-574-5p) and miR-574-5p overexpression vector were synthesized by Shanghai Bioengineering Co., Ltd. (Shanghai, China);

[0056] (2) Prepare miR-NC and miR-574-5p overexpression vectors in advance and store them at 4°C for future use;

[0057] (3) Add 250 μL Opti-MEM medium and 5 μL Lipo 2000 to a 5 mL centrifuge tube, gently pipette about 30 times, let stand, and incubate at room temperature for 5 min;

[0058] (4) Take two 1.5 mL centrifuge tubes without RNase, add miR-NC and miR-574-5p into the centrifuge tubes respectively, and add 250 μL Opti-MEM medium to each tube, gently pipette about 5 times, let it stand, and incubate at room temperature for 5 minutes;

[0059] (5) Mix (3) and (4) evenly, pipette gently for about 5 times, let stand, and incubate at room temperature for 20 min;

[0060] (6) Discard the old culture medium, wash once with PBS, and add 1.5 mL of Opti-MEM culture medium to each well for later use;

[0061] (7) Add 500 μL of the mixed solution in step (5) to each well, mark the well, and place the well in the incubator for another 6 h.

[0062] (8) After 6 h, the original culture medium was discarded, and 2 mL of DMEM culture medium containing melanosomes (obtained in Example 4) was added, and the culture was continued for 48 h.

[0063] MTT assay was used to detect cell viability after cell transfection:

[0064] 1) 1×10 cells were inoculated into each well of a 96-well culture plate 5 The cells were cultured for 18 h, miR-NC and miR-574-5p were transferred into the cells, and the culture was continued for 48 h.

[0065] 2) Add 15 μL (5 mg / mL) MTT solution to each well, continue culturing for 4 h, and discard the supernatant;

[0066] 3) Add 150 μL DMSO to each well and shake for 10 min until the purple crystals are completely dissolved;

[0067] 4) The OD value was detected at 490 nm. The cells only added with lipo 2000 were used as the control group, and the cells only added with DMEM medium were used as the blank group. At least three biological replicates were performed, and the experiment was repeated three times independently.

[0068] Calculation of cell viability:

[0069] The results are as follows Figure 4 As shown, compared with the miR-NC group, transfection of miR-574a-5p overexpression vector had no obvious cytotoxicity to keratinocytes and did not affect the cell viability of keratinocytes.

[0070] Melanin content detection:

[0071] 1) Collect the keratinocyte precipitate, add 1 mL of NaOH (1 M, containing 10% DMSO) solution, and incubate at 80°C for 1 h;

[0072] 2) Pipette and mix well, add the lysed solution to a 96-well culture plate, add 200 μL to each well;

[0073] 3) Measure OD value at 475 nm.

[0074] Calculate the intracellular melanin content:

[0075]

[0076] The results are as follows Figure 5 As shown, the cells in the miR-NC transfection group were polygonal in morphology, grew vigorously, were plump, had clear edges, grew adherently, and had more melanin ( Figure 5 A, 5C); Compared with the miR-NC group, after overexpression of miR-574-5p, the morphology of Hacat cells did not change significantly, but the melanin was significantly reduced ( Figure 5 B, 5C)

[0077] In summary, according to the embodiments of the present invention, after treating mouse B16 melanoma cells with ceramide Ehux-C22, the expression of secreted exosomal miR-574-5p was induced. MiR-574-5p can significantly inhibit the transport of melanosomes to human keratinocytes, providing a novel and feasible exosomal miRNA raw material for whitening skin care products.

[0078] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms should not be understood as necessarily being directed to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine different embodiments or examples described in this specification.

[0079] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.

Claims

1. Use of exosomal miR-574-5p in the preparation of a drug for inhibiting melanosome transport, characterized in that: After treating mouse B16 melanoma cells with ceramide Ehux-C22, the expression of secreted exosome miR-574-5p was induced, and then the B16 cell exosomes were extracted by ultracentrifugation to obtain the exosome miR-574-5p.

2. The use according to claim 1, characterized in that The ceramide Ehux-C22 is extracted from the marine coccolithophore Emiliania huxley BOF92.

3. The use according to claim 1, characterized in that The exosomal miR-574-5p inhibits the transport of melanosomes to human keratinocytes.

4. The use according to claim 1, characterized in that The final concentration of the ceramide Ehux-C22 was 2 μM.

5. Application of exosome miR-574-5p in the preparation of skin whitening cosmetics, characterized in that: After treating mouse B16 melanoma cells with ceramide Ehux-C22, the expression of secreted exosome miR-574-5p was induced, and then the B16 cell exosomes were extracted by ultracentrifugation to obtain the exosome miR-574-5p.